Study Comparing 0.5mg of Ranibizumab and Higher Doses in the Treatment of Clinically Significant Diabetic Macular Edema

Completed · Phase 1/Phase 2

Conditions studied: Clinically Significant Diabetic Macular Edema

In brief

The purpose of this study is to evaluate the safety and tolerability of Ranibizumab in patients with Clinically Significant Diabetic Macular Edema (CSDME). It will also compare treatment outcomes for patients receiving 0.5mg Ranibizumab and higher doses of 1.0mg and 2.0mg Ranibizumab.

Key facts

Study ID

NCT00440609

Run by

Philip J. ferrone, M.D.

People needed

50

Starts

2007-03-01

Expected to finish

2012-12-01

Last updated by the study team

2013-08-02

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Type I or Type II diabetic subjects
• Vision between 20/20 and 20/400
• Presence of Clinically Significant Diabetic Macular Edema

You may not qualify if…

• Presence of any condition that would prevent clear visualization of the back of the eye
• Uncontrolled glaucoma
• Complications of glaucoma
• Inflammation inside the eye
• Certain prior eye surgeries, other than cataract surgery
• Other eye diseases that may compromise the vision in the study eye
• Certain prior eye treatments
• Pregnancy
• Uncontrolled health conditions
• History of heart attack
• History of stroke
• Current participation in another investigational trial

Where it is running

• Long Island Vitreoretinal Consultants — Great Neck, New York, United States
• Long Island Vitreoretinal Consultants — Hauppauge, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.